Absci Started by Guggenheim at Buy on Pioneer Status in AI Drug Design
Absci Initiated at Buy by Guggenheim
Guggenheim Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $10
Is Absci (NASDAQ:ABSI) Using Debt In A Risky Way?
AI pharmaceutical "new star" favored by top venture capital Thrive Capital and OpenAI.
AI pharmaceutical startup Chai Discovery raised nearly $30 million in its latest seed round of financing, with investors including well-known investment firms Thrive Capital and OpenAI. The company's goal is to transform biology from a science to engineering through AI technology, making the drug development process more efficient. The company released its first open-source molecular structure model, Chai-1, on Monday, outperforming Google's AlphaFold and ESM3. In the AI drug development field, Chai faces competition from other startups and tech giants like Google, the latter predicting the market size to potentially exceed $100 billion.
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating
